Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/05/2008
Trade Name:
Arimidex
Generic or Proper Name (*):
anastrozole
Indications Studied:
Male pubertal patients with gynecomastia and female pediatric patients with McCune-Albright syndrome with progressive precocious puberty
Therapeutic Category:
Estrogen lowering agent
Ages Studied:
10 years and older
Study #:
3
Study Type:
Pharmacokinetic/Pharmacodynamic
Study Design:
Open Label/Traditional Pharmacokinetic
No Patients:
38
No Centers:
2
No Countries:
1
BPCA(B), PREA(P):
B
Asian:
0
Black:
9
Other:
4
White:
25
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
5
Non-Hispanic/Non Latino:
0
-
-